C4 Therapeutics (CCCC) CMO Reyno Leonard Receives 15,325 Shares

What Happened
Reyno Leonard, Chief Medical Officer of C4 Therapeutics (CCCC), acquired 15,325 shares on July 10, 2026 upon vesting/settlement of previously granted RSUs (transaction code M). To satisfy tax withholding obligations, 7,397 of those shares were withheld by the company (transaction code F) at $4.06 per share, representing $30,032. After withholding, Leonard retained a net 7,928 shares. This was not an open-market purchase or sale but the settlement of equity awards.

Key Details

• Transaction date: July 10, 2026; Form 4 filed July 13, 2026 (timely filing).
• Exercise/conversion (M): 15,325 shares acquired at $0.00 exercise price.
• Tax withholding (F): 7,397 shares withheld at $4.06 per share; withholding value = $30,032. This withholding is not a sale by the reporting person (per footnote).
• Net shares added to holdings: 7,928 shares retained after withholding.
• Footnotes: F1 notes these shares are from the vesting/settlement of RSUs originally reported July 12, 2023; F2 clarifies withheld shares were used to satisfy tax obligations and are not sales.

Context
This was an equity award vesting event, not a market trade. RSU vesting and issuer withholding for taxes (a common cashless withholding mechanism) do not necessarily indicate insider sentiment about the company's stock. The M code here reflects conversion/settlement of the derivative award (RSUs) into common stock, followed by issuer withholding to cover taxes.